BACKGROUND: There is a need to improve the systemic treatment of advanced adenoid cystic carcinoma (ACC). Response rates to chemotherapy are poor and preliminary investigations of molecularly targeted agents have been disappointing. In this study, we evaluate sorafenib, an oral multikinase inhibitor, which has an attractive targeting profile for this disease. METHODS: In a single-arm phase II trial, patients with unresectable locally recurrent and/or metastatic ACC were treated with sorafenib 400 mg bid. RESULTS: Twenty-three patients, median age 51 years, were recruited from 2009 to 2011. Median progression-free survival (PFS) and overall survival (OS) were 11.3 and 19.6 months, respectively. PFS at 6 and 12 months were 69.3% and 46.2%, respectively. Sorafenib was only reasonably well tolerated, and 13 patients (57%) experienced grade 3 toxicity. CONCLUSION: Sorafenib showed modest activity in ACC with a 12-month PFS of 46.2%. Sorafenib 400 mg bid was associated with significant toxicity and, taken together with limited effectiveness, cannot be enthusiastically recommended for further evaluation.
BACKGROUND: There is a need to improve the systemic treatment of advanced adenoid cystic carcinoma (ACC). Response rates to chemotherapy are poor and preliminary investigations of molecularly targeted agents have been disappointing. In this study, we evaluate sorafenib, an oral multikinase inhibitor, which has an attractive targeting profile for this disease. METHODS: In a single-arm phase II trial, patients with unresectable locally recurrent and/or metastatic ACC were treated with sorafenib 400 mg bid. RESULTS: Twenty-three patients, median age 51 years, were recruited from 2009 to 2011. Median progression-free survival (PFS) and overall survival (OS) were 11.3 and 19.6 months, respectively. PFS at 6 and 12 months were 69.3% and 46.2%, respectively. Sorafenib was only reasonably well tolerated, and 13 patients (57%) experienced grade 3 toxicity. CONCLUSION:Sorafenib showed modest activity in ACC with a 12-month PFS of 46.2%. Sorafenib 400 mg bid was associated with significant toxicity and, taken together with limited effectiveness, cannot be enthusiastically recommended for further evaluation.
Authors: Vatche Tchekmedyian; Eric J Sherman; Lara Dunn; Crystal Tran; Shrujal Baxi; Nora Katabi; Cristina R Antonescu; Irina Ostrovnaya; Sofia S Haque; David G Pfister; Alan L Ho Journal: J Clin Oncol Date: 2019-04-02 Impact factor: 44.544
Authors: Patrick M Dillon; Gina R Petroni; Bethany J Horton; Christopher A Moskaluk; Paula M Fracasso; Michael G Douvas; Nikole Varhegyi; Snjezana Zaja-Milatovic; Christopher Y Thomas Journal: Clin Cancer Res Date: 2017-04-04 Impact factor: 12.531
Authors: A L Ho; L Dunn; E J Sherman; M G Fury; S S Baxi; R Chandramohan; S Dogan; L G T Morris; G D Cullen; S Haque; C S Sima; A Ni; C R Antonescu; N Katabi; D G Pfister Journal: Ann Oncol Date: 2016-08-26 Impact factor: 32.976
Authors: Shruti Choudhary; Arpit Doshi; Lerin Luckett-Chastain; Michael Ihnat; Ernest Hamel; Susan L Mooberry; Aleem Gangjee Journal: Bioorg Med Chem Date: 2021-02-12 Impact factor: 3.641
Authors: Young Kwang Chae; Su Yun Chung; Andrew A Davis; Benedito A Carneiro; Sunandana Chandra; Jason Kaplan; Aparna Kalyan; Francis J Giles Journal: Oncotarget Date: 2015-11-10
Authors: Priscila H Goncalves; Lance K Heilbrun; Michael T Barrett; Shivaani Kummar; Aaron R Hansen; Lillian L Siu; Richard L Piekarz; Ammar W Sukari; Joseph Chao; Mary Jo Pilat; Daryn W Smith; Lindsay Casetta; Scott A Boerner; Alice Chen; Elizabeth Lenkiewicz; Smriti Malasi; Patricia M LoRusso Journal: Oncotarget Date: 2017-05-16